
Collagen II, Mouse, mAb CIIC1
The monoclonal antibody CIICI reacts with the C1 epitope (triple helical position 358-364) of collagen type II. Collagen is a structural protein in bone, cartillage and connective tissue. Collagen type II (CII) is the major collagen of the nucleus pulposa (a component of spine), cartilage and vitreous (a component of the eye). The most commonly used animal model for rheumatoid arthritis (RA) is the collagen-induced arthritis (CIA). Transfer of collagen type II specific monoclonal antibodies induces an acute form of arthritis (collagen type II antibody induced arthritis, CAIA). The monocolonal antibody CIIC1 has been shown to induce CAIA in naïve mice after injection of lipopolysacharide (LPS). However, in combination with the monoclonal antibody M2139, binding to the J1 epitope of CII, the pair of monoclonal antibodies induce arthritis in different strains of mice without any other stimulants. The presence of secondary stimulus, LPS, increases the disease incidence and severity. The monoclonal antibody CIIC1 is cross reactive with rat, bovine, chicken and human CII.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis